tiprankstipranks
Trending News
More News >
NeoGenomics (NEO)
NASDAQ:NEO
Advertisement

NeoGenomics (NEO) AI Stock Analysis

Compare
1,868 Followers

Top Page

NEO

NeoGenomics

(NASDAQ:NEO)

Rating:51Neutral
Price Target:
$6.50
▲(1.25%Upside)
NeoGenomics' overall stock score is primarily influenced by its financial performance, which shows growth but significant profitability challenges. Technical analysis indicates bearish trends, while recent earnings call and corporate events provide a positive outlook, particularly in strategic initiatives and market positioning.
Positive Factors
Acquisitions
The Pathline acquisition should improve turnaround times in the Northeast, enabling NEO to win new market share.
Clinical Performance
Clinical test volume was up 8% year-over-year, exceeding expectations.
Revenue Growth
NEO's blended gross margin increased by approximately 210 basis points year-over-year to 44%.
Negative Factors
Management Changes
The recent management changes, including the departure of the former CEO and appointment of a new CEO, raise the risk of further senior management turnover.
Market Competition
The NGS solid tumor CGP market is becoming more competitive, making a 25% growth expectation for 2025-26 unlikely to materialize.
Revenue Outlook
The growth outlook for NeoGenomics Inc. appears challenging with an overly aggressive guidance for 2025.

NeoGenomics (NEO) vs. SPDR S&P 500 ETF (SPY)

NeoGenomics Business Overview & Revenue Model

Company DescriptionNeoGenomics, Inc. is a leading provider of cancer-focused genetic testing services and oncology-related clinical and pharmaceutical services. The company operates in the healthcare sector, specializing in diagnostic testing services across various modalities, including cytogenetics, flow cytometry, immunohistochemistry, molecular testing, and pathology consultation. NeoGenomics serves a diverse client base, including pathologists, oncologists, hospitals, research institutions, and pharmaceutical companies, with the goal of improving patient care through precise and timely diagnostic insights.
How the Company Makes MoneyNeoGenomics generates revenue primarily through offering specialized diagnostic testing services to healthcare providers and pharmaceutical companies. The company's revenue model is based on laboratory service fees charged for each test conducted. This includes routine testing as well as more complex molecular and genetic tests. NeoGenomics also derives income from its pharmaceutical services segment, where it partners with pharmaceutical and biotech companies to support clinical trials and drug development through laboratory testing and consultative services. Key revenue streams include testing services for community-based pathology practices, hospitals, and health systems, as well as strategic collaborations with pharmaceutical companies for research and development projects. Significant factors contributing to its earnings include its expansive testing menu, advanced technological capabilities, and a strong focus on personalized medicine in oncology.

NeoGenomics Earnings Call Summary

Earnings Call Date:Apr 29, 2025
(Q1-2025)
|
% Change Since: -35.61%|
Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment overall, with significant growth in revenue and EBITDA, expansion through acquisitions, and strong performance in clinical testing volumes and NGS revenue. However, there were challenges in the non-clinical sector, particularly in pharma and biotech spending. Despite these challenges, the company's strategic initiatives and market positioning in oncology provide a robust outlook.
Q1-2025 Updates
Positive Updates
Record Revenue and EBITDA Growth
NeoGenomics reported revenues of $168 million and adjusted EBITDA of $7.1 million for Q1 2025, marking a 100% improvement over the prior year and the seventh consecutive quarter of positive adjusted EBITDA.
Clinical Testing Volume Increase
Clinical testing volumes increased by 8% compared to the previous year, with a 3% increase in revenue per test.
NGS Revenue Growth
NGS revenue grew by 18% in Q1 2025, with five new NGS products accounting for 22% of total clinical revenue.
Pathline Acquisition
NeoGenomics acquired Pathline, expanding their capabilities in the Northeast, expected to contribute $12-14 million in revenue for 2025.
Negative Updates
Non-Clinical Revenue Decline
Non-clinical revenue declined by $3.4 million or 15.8%, impacted by macroeconomic factors such as tariffs and uncertainties in NIH funding.
Challenges in Pharma Sector
Pharma and biotech spending has not rebounded, impacting non-clinical revenues. RaDaR 1.0 trials have wrapped up, and new contracts cannot be sold.
Company Guidance
During the NeoGenomics First Quarter 2025 Conference Call, the company provided updated guidance for the fiscal year 2025. NeoGenomics raised its full-year revenue guidance to a range of $747 million to $759 million, reflecting 13% to 15% growth, driven by strong clinical volume growth and the recent acquisition of Pathline. The company reaffirmed its adjusted EBITDA guidance of $55 million to $58 million. Key metrics highlighted included first-quarter revenue of $168 million, a 102% year-over-year increase in adjusted EBITDA to $7.1 million, and an 8% increase in clinical testing volumes. The acquisition of Pathline is expected to contribute $12 million to $14 million in revenue for 2025, with anticipated incremental revenue and cost synergies materializing in 2026 and beyond. The company also noted ongoing challenges in the non-clinical segment due to broader macroeconomic conditions but expressed confidence in offsetting these with strong clinical performance.

NeoGenomics Financial Statement Overview

Summary
NeoGenomics is experiencing revenue growth but faces significant profitability challenges. The company has high leverage and negative cash flow, indicating a need for better operational efficiency and cost control.
Income Statement
45
Neutral
NeoGenomics has shown a steady increase in total revenue over recent years, with a TTM revenue of $672 million, indicating a growth trajectory. However, persistent negative EBIT and net income indicate ongoing profitability challenges, with negative margins across gross, EBIT, and net profit. The company needs to focus on cost management and operational efficiency to achieve profitability.
Balance Sheet
55
Neutral
The company maintains a healthy equity ratio with stockholders' equity representing a significant portion of total assets. However, the debt-to-equity ratio remains elevated, reflecting a reliance on debt financing. Positive equity growth is a strength, but the high leverage poses potential risks, particularly given the current lack of profitability.
Cash Flow
50
Neutral
Operating cash flow remains positive in the TTM, an improvement from previous periods, although free cash flow is still negative due to high capital expenditures. The company has shown improvement in cash management, but achieving positive free cash flow is critical for long-term sustainability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue660.57M591.64M509.73M484.33M444.45M
Gross Profit290.10M244.60M187.90M187.06M185.89M
EBITDA-1.51M-17.61M-82.33M46.50M34.85M
Net Income-78.73M-87.97M-144.25M-8.35M4.17M
Balance Sheet
Total Assets1.64B1.68B1.74B1.87B988.33M
Cash, Cash Equivalents and Short-Term Investments386.84M415.20M437.99M515.39M296.26M
Total Debt605.33M611.68M610.93M612.79M218.22M
Total Liabilities735.70M739.69M742.01M761.50M294.04M
Stockholders Equity902.34M941.54M998.02M1.11B694.29M
Cash Flow
Free Cash Flow-34.04M-30.70M-96.88M-90.86M-27.64M
Operating Cash Flow7.02M-1.95M-65.99M-26.72M1.46M
Investing Cash Flow12.86M76.71M517.00K-632.37M-159.44M
Financing Cash Flow4.65M4.55M11.83M725.28M235.60M

NeoGenomics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.42
Price Trends
50DMA
7.29
Negative
100DMA
8.26
Negative
200DMA
11.60
Negative
Market Momentum
MACD
-0.27
Positive
RSI
36.57
Neutral
STOCH
21.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEO, the sentiment is Negative. The current price of 6.42 is below the 20-day moving average (MA) of 7.03, below the 50-day MA of 7.29, and below the 200-day MA of 11.60, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 36.57 is Neutral, neither overbought nor oversold. The STOCH value of 21.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEO.

NeoGenomics Risk Analysis

NeoGenomics disclosed 40 risk factors in its most recent earnings report. NeoGenomics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

NeoGenomics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
$730.53M11.3921.57%25.92%
64
Neutral
$485.05M30.59-1.20%38.43%86.19%
56
Neutral
$1.11B-3.04%-13.79%82.82%
52
Neutral
$574.78M-3.61%1.71%76.00%
51
Neutral
$850.67M-8.57%10.10%8.79%
50
Neutral
AU$2.60B2.95-57.47%2.44%36.73%13.67%
43
Neutral
$436.92M-13.84%7.38%60.45%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NEO
NeoGenomics
6.42
-8.66
-57.43%
MYGN
Myriad Genetics
4.65
-23.20
-83.30%
OPK
Opko Health
1.40
-0.02
-1.41%
CDNA
CareDx
13.12
-5.75
-30.47%
FLGT
Fulgent Genetics
18.41
-4.58
-19.92%
CSTL
Castle Biosciences
16.43
-2.88
-14.91%

NeoGenomics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
NeoGenomics Expands Board, Appoints New Director
Positive
Jun 24, 2025

On June 19, 2025, NeoGenomics, Inc. expanded its Board of Directors from nine to ten members and appointed Marjorie C. Green as a new director. Dr. Green, who is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck, brings extensive experience in oncology and business development. Her appointment is expected to enhance NeoGenomics’ strategic direction in the precision oncology market, aligning with the company’s mission to improve patient care.

The most recent analyst rating on (NEO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.

Executive/Board ChangesShareholder Meetings
NeoGenomics Approves Key Proposals at Annual Meeting
Neutral
May 27, 2025

On May 22, 2025, NeoGenomics, Inc. held its annual stockholders meeting where several key proposals were approved. These included an amendment to the 2023 Equity Incentive Plan, which increased the number of shares authorized for issuance and established a minimum vesting period, among other changes. Additionally, the election of nine directors to the Board and the approval of executive compensation were confirmed. The stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accountant.

The most recent analyst rating on (NEO) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025